Dirven, I.; Pierre, E.; Vander Mijnsbrugge, A.-S.; Vounckx, M.; Kessels, J.I.; Neyns, B.
Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases. Cancers 2024, 16, 4083.
https://doi.org/10.3390/cancers16234083
AMA Style
Dirven I, Pierre E, Vander Mijnsbrugge A-S, Vounckx M, Kessels JI, Neyns B.
Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases. Cancers. 2024; 16(23):4083.
https://doi.org/10.3390/cancers16234083
Chicago/Turabian Style
Dirven, Iris, Eden Pierre, An-Sofie Vander Mijnsbrugge, Manon Vounckx, Jolien I. Kessels, and Bart Neyns.
2024. "Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases" Cancers 16, no. 23: 4083.
https://doi.org/10.3390/cancers16234083
APA Style
Dirven, I., Pierre, E., Vander Mijnsbrugge, A.-S., Vounckx, M., Kessels, J. I., & Neyns, B.
(2024). Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases. Cancers, 16(23), 4083.
https://doi.org/10.3390/cancers16234083